Remove clinical gout
article thumbnail

Gout market across 7MM set to reach $10.8 bn in 2032 fueled by novel ULTs and rising prevalence: GlobalData

Express Pharma

The sales growth of gout therapies across the seven major markets (7MM: the US, 5EU, and Japan) is set to increase at a compound annual growth rate (CAGR) of 8.8 These therapies are likely to adopted for patients with chronic gout or with hyperuricemia that is likely to lead to gout in the long-term. per cent from $4.6

article thumbnail

Arthrosi’s gout drug financed with $75 million Series D

Outsourcing Pharma

company Arthrosi Therapeutics has bagged $75 million in a Series D round to fund the clinical development of a small molecule drug for chronic gout.

96
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Allopurinol Versus Febuxostat – Clinical Comparison

Med Ed 101

Lowering uric acid is the key to reducing gout flares. The post Allopurinol Versus Febuxostat – Clinical Comparison appeared first on Med Ed 101. Both allopurinol (podcast) and febuxostat are effective at performing this task. I’ll break down some of those comparisons in this article.

105
105
article thumbnail

Febuxostat: Increased Risk of Cardiovascular Death and All-cause Mortality

RX Note

Drug Safety Update In 2009, febuxostat (non-purine selective xanthine oxidase inhibitor) was approved by US Food and Drug Administration (FDA) to treat gout , but with a warning and precaution regarding possible cardiovascular events. The manufacturer was required to conduct a large post-marketing safety clinical trial.

40
article thumbnail

Probenecid Clinical Pearls

Med Ed 101

Probenecid can be used for patients who have gout. The drug lowers uric acid levels which can help prevent future gout flares. The post Probenecid Clinical Pearls appeared first on Med Ed 101. Here […].

40
article thumbnail

FDA expands approval for Horizon’s Krystexxa for uncontrolled gout

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has granted approval for the supplemental Biologics License Application (sBLA) of Horizon Therapeutics for the Krystexxa (pegloticase) injection, given along with methotrexate, to help uncontrolled gout patients attain a complete response to treatment.

article thumbnail

2020 Gout Guidelines – Important Takeaways

Med Ed 101

Recently, the American College of Rheumatology released new 2020 gout guidelines. In these guidelines, there are 42 recommendations that reflect new clinical evidence since the release of the 2012 guidelines. Full text 2020 gout guidelines can be found here.

40